Asymmetric interfering RNA compositions that silence K-RAS and methods of uses thereof

A technology of gene silencing and nucleotides, applied in the field of compositions for silencing K-Ras gene expression, can solve problems such as the unknown role of oncogenes

Inactive Publication Date: 2017-12-01
1GLOBE BIOMEDICAL CO LTD
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the role of oncogenes such as

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Asymmetric interfering RNA compositions that silence K-RAS and methods of uses thereof
  • Asymmetric interfering RNA compositions that silence K-RAS and methods of uses thereof
  • Asymmetric interfering RNA compositions that silence K-RAS and methods of uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0139] Example 1: In vitro potency of aiK-Ras

[0140] Figure 1(A) shows in vitro studies using aiRNA ID NO: 21 ("aiK-Ras#1") targeting the K-Ras target SEQ ID NO: 22 to determine the IC of aiK-Ras#1 50 . DLD1 cells (ATCC) were transfected with aiK-Ras#1. Forty-eight hours after transfection, cells were collected and RNA was isolated. Determination of the IC of aiK-Ras#1 ​​by qPCR 50 . The remaining mRNAs were normalized to GAPDH expression levels. IC 50 It is 3.1pM, indicating that aiK-Ras#1 ​​efficiently silences K-Ras gene expression.

[0141] Figure 1(B) shows an in vitro study using aiRNA ID NO: 142 ("aiK-Ras#2") targeting the K-Ras target SEQ ID NO: 142 to determine the IC of aiK-Ras#2 50 . DLD1 cells were transfected with aiK-Ras#2. Forty-eight hours after transfection, cells were collected and RNA was isolated. Determination of the IC of aiK-Ras#2 by qPCR 50 . The remaining mRNAs were normalized to GAPDH expression levels. IC 50 It is 3.5pM, indicating ...

Embodiment 2

[0142] Example 2: Off-target effects of aiK-Ras reduction

[0143] Figure 2(A) shows detection of siRNA and aiRNA loaded in RISC by northern blot analysis. To analyze small RNA RISC loading, HEK293Flag-Ago2 stable cell lines were transfected with aiRNA or siRNA duplexes. Cells were lysed at indicated time points and co-immunoprecipitated with Flag antibody (Sigma, Catalog #F1804). The immunoprecipitate was washed, RNA was extracted from the complex with TRIZOL (Life Technologies, 15596-018), and loaded onto 15% TBE-Urea PAGE or 15% TBE non-denaturing PAGE gel. After electrophoresis, transfer RNA to Hybonad-XL Nylon membrane. The r-P32-labeled probe for detecting the sense or antisense strand is then hybridized to the RNA on the membrane. HEK293 cells expressing Flag-Ago2 (Invivogen, Catalog#293-null) were transfected with siRNA or aiRNA, and then co-immunoprecipitation assay was performed. FLAG-Ago2 HEK293 cells stably expressing FLAG-Ago2 were formed by transient transf...

Embodiment 3

[0146] Example 3: aiK-Ras sensitivity in K-Ras mutant cells

[0147] Fig. 3(A) shows the colony formation assay of AGS (ATCC) and DLD1 transfected with aiK-Ras#1 ​​or aiK-Ras#2. Cells were transfected with 1 nM GFP aiRNA (control; GGTTATGTACAGGAACGCA (SEQ ID NO: 956)) or 1 nM aiK-Ras#1 ​​or aiK-Ras#2 for 24 hours. Cells were then trypsinized and transferred to 6-well plates at 500-2000 cells / well to test the clonogenicity of the cells. After 11-14 days, colonies were stained with Giemsa stain and counted. For western blot analysis, the cells were washed with ice-cold PBS, in lysis buffer [50mM Hepes (pH 7.5), 1% Nonidet P-40, 150mM NaCl, 1mM EDTA, 1X Halt Proteasome Inhibitor Cocktail (Thermo Scientific, Catalog #87786)]. Solubilized proteins (10 μg) were separated by SDS / PAGE and transferred to PVDF membranes. Primary antibodies were used in this assay. Antigen-antibody complexes were visualized by enhanced chemiluminescence (BioRad, Catalog #170-5060).

[0148] Figure ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides novel compositions for use in silencing K-Ras gene expression. More particularly, the invention provides novel asymmetrical interfering RNA molecules as inhibitors of K-Ras expression, and to pharmaceutical compositions and uses thereof in the treatment of cancer or a related disorder in a mammal.

Description

technical field [0001] The present invention generally relates to compositions for silencing K-Ras gene expression. More specifically, the present invention relates to a novel asymmetric interfering RNA molecule as an inhibitor of K-Ras expression, a pharmaceutical composition and its use in the treatment of mammalian cancer or related diseases. Background technique [0002] Gene silencing via RNAi (RNA interference) through the use of small or short interfering RNA (siRNA) has emerged as a therapeutic tool. However, in addition to outstanding delivery issues, the development of RNAi-based drugs faces challenges such as limited potency of siRNAs, non-specific effects of siRNAs, e.g., interferon-like responses and sense-strand-mediated off-target gene silencing, and interactions with Surprisingly high or prohibitive costs associated with siRNA synthesis. The gene silencing efficacy of siRNA is limited to about 50% or less for most genes in mammalian cells. The manufacture ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07H21/02C07H21/04C12N15/00
CPCA61P1/04A61P35/00A61P43/00C12N15/1135C12N2310/14A61K31/7105C12N2310/31C12Q1/6886C12Q2600/158G01N33/57446G01N2333/82G01N33/5748G01N2333/914
Inventor 李嘉强
Owner 1GLOBE BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap